WO2025169136 - DOSING REGIMEN FOR CD19 CAR NK CELLS IN TREATING CANCER
National phase entry is expected:
Publication Number
WO/2025/169136
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051308
International Filing Date
07.02.2025
Title **
[English]
DOSING REGIMEN FOR CD19 CAR NK CELLS IN TREATING CANCER
[French]
POSOLOGIE POUR CELLULES NK CAR CD19 DANS LE TRAITEMENT DU CANCER
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors
SELLNER, Leopold
REZVANI, Katy
MARIN COSTA, David
SHPALL, Elizabeth J.
Priority Data
63/551,881
09.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2956 | |
| EPO | Filing, Examination, Granting | 22906 | |
| Japan | Filing, Examination, Granting | 3016 | |
| South Korea | Filing, Examination, Granting | 3830 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
42,048
Contact Us
Abstract[English]
The present disclosure provides, among other things, a method for treating cancer by administering two or more doses of cord blood derived natural killer cells expressing CD19 targeted chimeric antigen receptor to a subject in need thereof. The present disclosure provides a dosing regimen, for example, 800 million CD19 CAR NK cells administered in three doses for treating a cancer, for example, relapsed or refractory large B cell lymphoma.[French]
La présente divulgation concerne, entre autres, une méthode de traitement du cancer par administration d'au moins deux doses de cellules tueuses naturelles dérivées du sang de cordon ombilical exprimant un récepteur antigénique chimérique ciblé par CD19 à un sujet dont l'état le nécessite. La présente divulgation concerne en outre une posologie, par exemple, 800 millions de cellules NK CAR CD19 administrées en trois doses pour traiter un cancer, par exemple, un lymphome à grandes cellules B récidivant ou réfractaire.